Is Oracle Still Attractively Priced After Its Recent 20% Pullback?

  • If you are wondering whether Oracle at around $178 a share is still a smart buy or if the easy money has already been made, this article will walk through what the numbers really say about its value.
  • Despite a sharp pullback in the short term, with the stock down about 20% over the last week and 18.8% over the past month, Oracle is still up 7.5% year to date and has delivered an impressive 193.0% gain over five years.
  • Recent headlines have focused on Oracle doubling down on cloud infrastructure and AI related partnerships, as the company pushes to win more workloads from enterprises modernizing their tech stacks. At the same time, investors are weighing how these big spending plans and shifting competitive dynamics might affect growth, margins, and ultimately what the stock is truly worth.
  • Right now, Oracle scores just 2/6 on our valuation checks. This suggests that some parts of the business may be priced richly while others could still offer upside. Next we will break down the standard valuation approaches investors use for Oracle, and then finish with a more holistic way to think about what the market might be missing.

Oracle scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Advertisement

Approach 1: Oracle Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow model estimates what a company is worth by projecting its future cash flows and discounting them back to today, using a rate that reflects risk and the time value of money.

For Oracle, the model starts with last twelve month Free Cash Flow of about $2.9 Billion and then uses analyst forecasts and longer term assumptions to map how that cash flow could evolve. Analyst estimates point to a period of volatile investment, with negative Free Cash Flow in the next few years, before recovering to around $22.7 Billion by 2030. Beyond the explicit analyst horizon, Simply Wall St extrapolates growth to build a 2 stage Free Cash Flow to Equity profile.

When all those projected cash flows are discounted back to today, the model arrives at an intrinsic value of roughly $164.68 per share. Compared with a market price around $178, the DCF implies the stock is about 8.4% overvalued. This is close enough to call it roughly in line with fair value rather than outright expensive.

Result: ABOUT RIGHT

Oracle is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

ORCL Discounted Cash Flow as at Dec 2025
ORCL Discounted Cash Flow as at Dec 2025

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Oracle.

Approach 2: Oracle Price vs Earnings

For profitable, established businesses like Oracle, the Price to Earnings ratio is a useful yardstick because it directly links what investors are paying to the profits the company is generating today. In general, companies with faster, more reliable earnings growth and lower perceived risk can justify a higher normal PE multiple, while slower growth or higher uncertainty usually caps how much investors are willing to pay.

Oracle currently trades on about 33.24x earnings, which is very close to the broader Software industry average of roughly 32.73x and sits at less than half the 68.38x average of its higher flying peers. Simply Wall St also calculates a Fair Ratio of 54.99x, a proprietary estimate of what Oracle’s PE should be once you factor in its earnings growth outlook, margins, industry, size and risk profile.

This Fair Ratio is more informative than a simple peer or sector comparison because it adjusts for Oracle’s specific fundamentals rather than assuming every software stock deserves the same multiple. With the Fair Ratio well above the current 33.24x, this framework suggests the market is still not fully pricing in Oracle’s earnings power.

Result: UNDERVALUED

NYSE:ORCL PE Ratio as at Dec 2025
NYSE:ORCL PE Ratio as at Dec 2025

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1463 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Oracle Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, a simple framework on Simply Wall St’s Community page. You connect the story you believe about a company to a concrete financial forecast and a clear Fair Value, then compare that to today’s Price to decide whether to buy, hold, or sell. The whole view updates dynamically as new earnings or news arrives. For example, one Oracle Narrative might see hypergrowth in AI infrastructure and a Fair Value near $390, while another more conservative Narrative might assume steadier cloud adoption and a Fair Value closer to $212. This shows how different yet reasonable perspectives on Oracle’s future revenue, margins, and risk can lead to very different but transparent valuation outcomes.

Do you think there's more to the story for Oracle? Head over to our Community to see what others are saying!

NYSE:ORCL 1-Year Stock Price Chart
NYSE:ORCL 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:ORCL

Oracle

Offers products and services that build, run and support enterprise information technology frameworks worldwide.

Exceptional growth potential, undervalued and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
46 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
65 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
CSBT.F logo
AnimalDoctorKwon on Kuros Biosciences ·

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

Fair Value:US$342.1892.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
RZLV logo
European_Hidden_Gem_Stocks on Rezolve AI ·

⚡ Two-Minute Drill: Rezolve AI - The AI That Doesn't Recommend Products. It Buys Them.

Fair Value:US$80.7897.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
NET logo
European_Hidden_Gem_Stocks on Netcall ·

⚡ Two-Minute Drill: Netcall PLC - This £200M AI Stock Is Already Running the NHS

Fair Value:UK£2.1745.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0